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Summary Pyrazinamide, the pyrazine analogue of nicotinamide, has been evaluated for its ability to modify
the radiation response of hypoxic cells both in vivo and in vitro. Results obtained with three different murine
tumour systems EMT6, LLC and SCCVII showed that pyrazinamide at a dose of 0.5 mg g' i.p. resulted in
enhanced radiation response. Dose modification factors of between 1.3 and 1.6 were observed using in vivo/in
vitro clonogenic assays. This enhancement was greater than that obtained in mouse intestine using crypt cell
survival as an endpoint (DMF 1.1). In contrast to the tumour data in vivo, the in vitro results indicate that
pyrazinamide displays little radiosensitising or toxic properties towards hypoxic CHO cells in culture. These
results suggest that pyrazinamide exerts its effects in vivo either by directly perturbing tumour physiology or by
being converted to an active metabolite. Blood flow studies performed using laser Doppler flowmetry indicate
that pyrazinamide produces a small (32%) increase in overall tumour blood flow in the SCCVII tumour.
Based on this finding, additional studies on tumour perfusion at the microregional level were performed in the
SCCVII tumour using a histological technique involving injection of fluorescent stains which demarcate
functional vasculature. The data show that when compared to saline injected controls, pyrazinamide reduced
the number of vessels opening and closing over a 20 min period from 10.2% to 3.8%. This finding suggests
that pyrazinamide may exert its effects at least in part by reducing the occurrence of acute hypoxia resulting
from dynamic changes in microregional perfusion.
Overcoming the problem of radioresistant hypoxic cells has
been a major focus of work in radiation biology over the last
three decades (Barendson et al., 1966; Coleman, 1988; Henk
et al., 1977; Hirst, 1986; Thomlinson & Gray, 1955). Much of
the research in this area has been centred on identifying
chemical agents which can selectively increase the radiation
response of these cells (Adams et al., 1976; Adams, 1984;
Brown, 1989). Many agents have been identified which can
reduce the problem of radiobiologically hypoxic cells either
through direct radiosensitisation (Adams et al., 1976; Brown
1989) or by improved oxygen delivery (Teicher & Rose, 1984;
Hirst & Wood, 1989). However, to date the success of such
chemical intervention in improving clinical response to radia-
tion treatment has been limited (Dische, 1989). Progress in
the search for more effective drugs can take two lines. One is
to develop more efficient and/or less toxic derivatives of an
already identified group of agents (Adams et al., 1979; Brown
& Workman, 1980). The other is to identify new groups of
chemicals which can modulate radiation response of hypoxic
cells. One group ofcompounds which is becoming of increas-
ing interest is those related to the benzamide structure.
Studies in recent years with the benzamide analogue
nicotinamide have identified it as an effective modifier of the
hypoxic response of tumours in vivo (Johnsson et al., 1985;
Horsman et al., 1986, 1987, 1988). Screening a number of
custom synthesised analogues of nicotinamide has not as yet
identified any superior compounds (Horsman et al., 1986).
However, one compound certainly worthy of investigation,
based on the fact that it is used clinically, is the pyrazine
analogue of nicotinamide, pyrazinamide (Weinstein, 1975). In
the present study we have evaluated the radiosensitising effect
of pyrazinamide in three murine tumours.
Materials and methods
Tumour systems
The three tumour systems used were the EMT6 grown in
Balb/C mice, the Lewis lung carcinoma (LLC) grown in
C57B1/6 mice and the squamous cell carcinoma SCCVII
grown in C3H/He mice (purchased from Charles River,
Quebec, Canada). Details of the derivation and maintenance
of these lines have been described previously (Rockwell et al.,
1972; Chaplin et al., 1983; Olive et al., 1985). Solid tumours
were produced by either intradermal (EMT6) or subcutan-
eous (LLC, SCCVII) implantation in 2-3 month old female
mice. The site of implantation was, except where stated, over
the sacral region of the back. Treatments were caried out
when tumours reached a size of 150-300 mg (EMT6 and
LLC) or 300-600 mg (SCCVII).
Drugs
Pyrazinamide was purchased from Sigma (St Louis, MO,
USA). For in vivo studies it was dissolved in phosphate
buffered saline and injected IP at a dose of 0.5 mg g' in a
volume of 0.5 ml per 25 g mouse. Misonidazole was supplied
by Roche (Welwyn Garden City, UK). Hoechst 33342 was
purchased from Sigma (St Louis, MO, USA) dissolved in
PBS and injected i.v. via the lateral tail vein at a dose of
15 fig g-' in a volume of 0.05 ml per 25 g mouse. The carbo-
cyanine dye DiOC7(3) was purchased from Molecular Probes
Inc. (Eugene, OR, USA), dissolved in 75% dimethyl sulphox-
ide and injected i.v. at a dose of Lg g-' in a volume of
0.05 ml per 25 g mouse.
Irradiation procedure
The procedure was based on the technique described by
Sheldon and Hill (1977). Mice were restrained unanaesthe-
tised in individual Perspex boxes from which a portion of
lead shield had been cut to expose the posterior dorsum
bearing the tumour to a horizontal X-ray beam. LLC and
SCCVII tumours were irradiated using a 270 kVp X-ray
machine (dose rate 3.1 Gy min ', HVL 1.7 mm Cu). EMT6
tumours were irradiated using a 250 kVp X-ray machine
(dose rate 2.1 Gy min-', HVL 1.0 mm Cu).
For crypt cell survival studies, irradiation was given to the
whole body at a dose rate of 1.5 Gy min-' using a 270 kVp
X-ray machine (HVL 1.7 mm Cu).
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Assessment of tumour response
Tumour response was assayed by in vitro survival of tumour
cells. For the EMT6 tumours survival was determined, as
previously described (Horsman et al., 1984), by excising
tumours 18 h after irradiation. Two tumours were combined
for each data point. They were minced, enzymatically dis-
aggregated to produce a single cell suspension, centrifuged
(1,500 r.p.m.; 10 min) and the cells resuspended, counted,
serially diluted and plated in Waymouth's medium plus 15%
fetal calf serum (Gibco, Santa Clara, CA, USA) to determine
their colony-forming ability. Survival was expressed as frac-
tion of surviving cells per tumour. This is the product of the
plating efficiency and cell yield per gram of treated tumours
relative to that for untreated controls. With the LLC and
SCCVII tumours, cell viability was assessed using the soft
agar clonogenic assay (Courtenay, 1976). The excision pro-
cedure was similar to that described for the EMT6 tumour
model, except that cells were diluted and plated in alpha
medium plus 20% fetal calf serum (Gibco, Burlington,
Ontario, Canada). Survival was also expressed as the fraction
of surviving cells per tumour. Dose modification factors were
obtained from the data by determining the ratio of doses
required to give a survival level of 10-3 in the absence or
presence of drug.
Crypt cell survival
C3H/He mice with or without prior injection of
pyrazinamide were given whole body radiation and killed
84 h later. A small section of the jejunum was removed, fixed
in formalin and processed for paraffin sectioning. Five micro-
metre sections were prepared, stained with haemotoxylin and
eosin and scored for regenerating crypts. These values were
converted to crypt cells per circumference as described
previously (Withers & Elkind, 1970). A minimum of five
sections were counted in each of the three to five animals per
experimental group.
In vitro studies
Chinese hamster ovary (CHO) cells, grown in suspension in
alpha MEM with 10% fetal calf serum (Gibco, Burlington,
Ontario, Canada) were used to assess radiosensitising ability
and toxicity of pyrazinamide, essentially following the
methods used for misonidazole (Moore et al., 1976). Briefly,
a stirred suspension of CHO cells (2 x I05 cells ml-') was
incubated in medium with or without drug for I h at 37°C
prior to irradiation, with nitrogen flow used to remove
oxygen (for radiosensitisation). For toxicity assessment, a
small aliquot of cells was added at zero time to pregassed
(N2) medium at 37°C (final concentration again 2 x 105
cells ml-') with or without drug. In both cases, aliquots were
removed after the given dose or incubation time, washed and
plated for clonogenic ability.
Laser dopplerflowmetry
Details of this technique are described in detail elsewhere
(Shepherd et al., 1987; Trotter et al., 1989a). Relative
changes in tumour red blood cell (RBC) flow following intra-
peritoneal administration of pyrazinamide were determined
using a laser doppler flowmeter (TSI Inc., St Paul, MN,
USA). Mice bearing a SCCVII tumour on the foot
(150-250 mg) were restrained in a jig and the tumour bear-
ing foot immobilised using surgical tape. Measurements were
made using a laser doppler probe (0.7 mm diameter) placed
on the surface of the tumour. Pyrazinamide was injected,
after stable recording had been obtained, via an indwelling
i.p. catheter.
Measurement ofmicroregionalperfusion changes
The use of sequential injections of Hoechst 33342 and carbo-
cyanine -derivative DiOC7(3) to quantify changes in func-
tional tumour vasculature has been described in detail
previously (Trotter et al., 1989a,b,c). Briefly, the basis of the
technique stems from the properties of the two fluorescent
dyes, i.e. they have different fluorescence spectra permitting
selective visualisation of the stains; they have short plasma
distribution half lives after i.v. administration and their
diffusion properties are such that they provide selective stain-
ing of the cells bordering the functional vasculature (Olive et
al., 1985; Trotter et al., 1989b). For the present series of
experiments, Hoechst 33342 was administered i.v. to animals
bearing tumours on their backs at 15jlg g-' (in 0.05 ml PBS)
followed 20 min later by an i.v. injection of DiOC7(3) at
1 tcg g-' (in 0.05 ml of 75% DMSO). Five minutes after
DiOC7(3) the animals were killed, the tumours were then
excised, embedded, frozen and sectioned on a refrigerated
microtome. Fluorescence microscopy was performed using a
Zeiss microscope with epifluorescence condenser, 100 W mer-
cury light source, and Neofluor objectives. For each treat-
ment group five to 10 mice were used, each bearing one
tumour. A minimum of 1,000 blood vessels were counted for
each tumour and the percentage ofvessels marked with either
Hoechst 33342 or DiOC7(3), but not both dyes, was deter-
mined. This value was expressed as the 'staining mismatch'.
Results
The effect of pyrazinamide (0.5 mg g' i.p.) administered at
various times before or after irradiation of mice bearing
EMT6 or LLC tumours is shown in Figure 1. It can be seen
that pyrazinamide enhances radiation induced cell killing
when administered before radiation but has little or no effect
when administered post-irradiation. The maximum effect is
observed when pyrazinamide is administered 30-60 min
prior to the commencement of radiation treatment. In Figure
2 the effect of administering pyrazinamide (0.5 mgg-'i.p.)
45 min prior to radiation on the survival response obtained
with EMT6, LLC and SCCVII tumours is shown. Although
in the absence of radiation pyrazinamide does not affect
survival, it does increase tumour response in the presence of
radiation in all three tumour lines investigated. Dose modi-
fication factors obtained are between 1.3 and 1.6. In order to
ascertain if therapeutic gain could accrue from the use of
pyrazinamide we have assessed its effect on the radiation
response of mouse intestine using the crypt cell survival end
point. The results shown in Figure 3 demonstrate that
pyrazinamide does enhance radiation induced damage to
crypt cells but to a lesser extent than seen with tumour. The
radiation response curve is shifted down in a parallel fashion
with a dose modification factor of between 1.0 and 1.2 over
the radiation dose range studied.
To establish the mechanism responsible for the enhance-
ment of tumour radiation response in vivo we have evaluated
the radiosensitising and toxic effects of pyrazinamide on
hypoxic cells in vitro. Figure 4 shows the radiation response
ofhypoxic CHO cells in vitro without drug or in the presence
of either 10mm misonidazole or 10mM pyrazinamide. While
misonidazole enhances radiation response of the cells (ER
approx. 2.2), pyrazinamide has no observable effect. Figure 5
shows the hypoxic toxicity of either 10mM misonidazole or
10mM pyrazinamide over a 5h incubation period. The
results clearly show that over this time period misonidazole is
cytotoxic to the hypoxic CHO cells while pyrazinamide has
no effect. The absence of cytotoxicity towards hypoxic cells
and lack of a marked effect of pyrazinamide on radiation
response in vitro would suggest that the in vivo effect results
either from a metabolite or from induced physiological
changes in the animal. The results in Figure 6 show red
blood cell (RBC) flow in SCCVII tumours as a function of
time after pyrazinamide (0.5 mg g-' i.p.). A small increase in
RBC flow occurs after drug administration. The maximum
increase was 32% which was reached 40-45 min after drug
administration. In addition to overall blood flow we have
assessed the effect of pyrazinamide on the dynamic micro-
regional heterogeneity of perfusion. Functional vasculature
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by injecting two fluorescent stains. For these experiments,
pyrazinamide (or saline) was injected i.p. 45 min prior to the
double staining procedure. Pretreatment with pyrazinamide
reduces the amount of perfusion mismatch in tumour com-
pared to saline treated controls (Figure 7). The percentage of
mismatched vessels was scored in central and peripheral
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tumour regions as well as overall. The values obtained (±
standard deviation) were (1) saline controls: central 14.5
(± 4.5), peripheral 7.8 (± 2.2), overall 10.3 (± 2.9); (2)
pyrazinamide pretreatment: central 4.4 (± 2.8), peripheral 2.6
(± 0.9), overall 3.2 (± 1.5); simultaneous stain injection: cen-
tral 1.6 (± 0.6), peripheral 1.1 (± 0.6), overall 1.3 (± 0.6).
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Figure 1 The effect of pyrazinamide (0.5 mg g- i.p.) administered at various times before (-) or after (+) a fixed dose ofX-rays.
Cell survival was assessed 18 h after radiation. Shaded areas represent the effect of X-rays alone ± standard deviation. X-ray dose
for EMT6 was 20 Gy, for LLC was 15 Gy.
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Figure 2 The effect of pyrazinamide (0.5 mg g-' i.p.) administered 45 min prior to radiation on the response of EMT6, LLC and
SCCVII tumour models. Cell survival was assessed 18 h after radiation. Lines were fitted for doses greater than 10 Gy by linear
regression analysis. (0) X-rays alone, (0) pyrazinamide 45 min prior to X-rays.
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Figure 3 Change in the response of mouse jejunum crypt cells to
X-rays, by pyrazinamide. Saline or pyrazinamide (0.5 mg g-')
was injected into non-tumour bearing mice 45 min prior to radia-
tion. Crypt cell survival was measured 84 h later. (0) saline plus
X-rays, (0) pyrazinamide plus X-rays. Mean ± I s.e. are shown.
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Figure 5 Cell survival as a function of time in hypoxia for CHO
cells. (0) no treatment, (A) in the presence of 10 mm
misonidazole, (0) in the presence of 10mm pyrazinamide.
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Figure 6 Relative RBC flow in SCCVII tumours as a function of
time following administration of pyrazinamide (0.5 mg g' i.p.).
Data points are mean ± standard deviation. A
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Figure 4 Radiation response of hypoxic CHO cells. (0) re-
sponse to X-rays alone, (A) X-rays plus 10mM miso, (0) X-rays
plus 10mM pyrazinamide.
Discussion
The results obtained show that pyrazinamide enhances the
radiation response of three different murine tumour lines.
Dose modification factors obtained for EMT6, LLC and
SCCVII tumours are 1.6, 1.5 and 1.3 respectively. This en-
hancement of radiation effects seen in tumours is higher than
the DMF of 1.0-1.2 obtained in mouse intestine, indicating
the potential for therapeutic gain. Studies designed to
indicate the mechanism of action of pyrazinamide suggest
that changes in microregional blood flow may be involved.
Saline Pyrazinamide Interval = 0
Figure 7 Effect of saline or pyrazinamide (0.5 mg g' i.p.) on
functional vasculature in 500-600 mg SCCVII tumours. Blood
vessels outlined by either Hoechst 33342 or DiOC7(3) but not
both are scored as mismatched. Both central and peripheral
tumour regions were scored. Interval = 0 represents the back-
ground mismatch when both stains are injected simultaneously.
Values represent mismatch scored in a minimum of 5 tumours for
each treatment with 1,000 vessels being scored in each tumour,
E mismatch scored in peripheral regions, X mismatch
scored in central regions, M mismatch scored in tumour
overall.
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The radiation dose modification factors obtained for
pyrazinamide in both tumours and intestine are comparable
with these previously reported with nicotinamide (Horsman
et al., 1986, 1987). The in vitro data show that unlike the
electron affinic radiosensitiser misonidazole, pyrazinamide
displays no radiosensitising or toxic effects on hypoxic cells
in culture. These comparisons were carried out at equimolar
doses of both pyrazinamide and misonidazole. These findings
suggest that pyrazinamide effects seen in vivo do not result
from a direct radiosensitising action or from hypoxic cell
cytotoxic effects of the parent molecule. This indicates that
other in vivo processes are operating. Pyrazinamide may be
metabolised in vivo to a product(s) which possesses direct
radiosensitising and/or toxic properties towards hypoxic cells.
Another possibility is that pyrazinamide (or a primary
metabolite) could modify physiological parameters within the
tumour resulting in a reduction in the radiobiologically
hypoxic fraction. One key parameter in determining the
number of hypoxic cells present in the tumour is oxygen
delivery. Recent studies with nicotinamide have shown that a
contributing factor to the radiosensitisation seen with this
compound is microregional changes in tumour blood flow
(Horsman et al., 1989; Chaplin et al., 1990); therefore, we
have sought to establish if similar effects occur after
pyrazinamide administration. Laser doppler flowmetry
studies in the SCCVII tumour indicate that pyrazinamide
produces a small (32%) but significant (P <0.05) increase in
blood flow in this tumour. However, this finding, although
indicating that blood flow changes can occur after
pyrazinamide, does not elucidate whether this reflects a small
increase in flow in all tumour vessels, or a large increase in
flow in a few vessels. This arises from the fact that although
laser doppler flowmetry measures flow in a relative small
volume (approx. 1 mm3) compared to other techniques, such
a volume still contains many blood vessels. The significance
of this limitation would be particularly important if
radiobiological hypoxia can occur from transient fluctuations
in microregional blood flow and thus oxygen delivery. Such
hypoxia is known to occur in experimental tumour systems
(Chaplin et al., 1986, 1987, 1990; Trotter et al., 1989b; Min-
chinton et al., 1990). Indeed, in the SCCVII tumour at a size
of 500mg, 8-10% of tumour vessels can open and close
during a 20min period (Trotter, 1989b). This latter study
utilised a histological procedure which can provide a map of
microregional blood flow (with resolution of single vessels) at
two instances in time. The technique appears well suited to
follow drug induced changes in functional vasculature (Trot-
ter, 1989c; Chaplin, 1990; Zwi et al., 1989). Using this techni-
que with the SCCVII tumour, our present studies de-
monstrate that pyrazinamide has a marked effect on transient
nonperfusion ofvessels. Staining mismatch was reduced from
10.3% to 3.2% by pretreatment with pyrazinamide. This
value is not significantly different from the background value
obtained when the two fluorescent stains are injected simul-
taneously. These data provide evidence that at least part of
the effect ofpyrazinamide may be mediated by a reduction in
'acate' radiobiological hypoxia resulting from transient
fluctuations in microregional perfusion. Similar results have
been recently reported with nicotinamide (Chaplin et al.,
1990).
The modification of tumour hypoxia may not afford a com-
plete explanation for the results obtained. This could be
inferred from two factors in the survival curves shown in Figure
2. One is that survival levels at radiation doses of 15 Gy and
above are higher than those expected from a totally aerobic
population (Chaplin & Horsman, unpublished results).
Secondly, the terminal slopes of the in vivo survival curves
from pyrazinamide pretreated animals do not become
parallel to the X-ray only curves, as would be expected if a
residual hypoxic fraction remained. These findings could
imply that some radiosensitising action (via a metabolite) is
superimposed on the physiological actions of pyrazinamide.
However, an alternative explanation which does not require
any radiosensitising component to exist is that the remaining
hypoxic cells after pyrazinamide pretreatment are diffusion
limited 'chronically' hypoxic cells which possess a more sen-
sitive radiation response than the acutely hypoxic cells
(Franko & Sutherland, 1979).
Overall, the in vivo and in vitro results obtained with
pyrazinamide bear a marked similarity to those previously
reported for nicotinamide, thus suggesting common
mechanisms of action. The fact that pyrazinamide is already
clinically used in the treatment of tuberculosis (Weinstein,
1975) and the results presented here strongly suggest further
studies with pyrazinamide and related analogues as modifiers
of tumour response to ionising radiation.
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